Drug intelligence / Profile preview

JSA-101

Development stage: Preclinical
Lead developer: CellMed
Modality: Small Molecules

Overview

JSA-101 is a synthetic small molecule drug candidate developed by CellMed for the treatment of cancer, with a primary focus on triple-negative breast cancer (TNBC). The drug was discovered using Computer-Aided Drug Design (CADD) and synthetic lethality strategies, which aim to identify and exploit specific genetic vulnerabilities within cancer cells. Although its precise molecular target has not been publicly disclosed by the developer, JSA-101 has been granted Orphan Drug Designation (ODD), reflecting its potential therapeutic importance for rare or difficult-to-treat oncological conditions.

Beyond the preview

Go deeper on JSA-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JSA-101.

Explore the full profile